NCT06771674 2025-09-09Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell CarcinomaHookipa Biotech GmbHCompleted662 enrolled
NCT03539198 2024-11-14Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck CancerMayo ClinicTerminated19 enrolled
NCT03652142 2018-08-29Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell CarcinomaAttikon HospitalUnknown50 enrolled